Towards an immunotherapy for p185HER2 overexpressing tumors.
Carter
P
P
Department of Protein Engineering, Genentech Inc., South San Francisco, CA 94080.
Rodrigues
M L
ML
Lewis
G D
GD
Figari
I
I
Shalaby
M R
MR
D000818:Animals; D018033:Antibodies, Bispecific / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D017252:CD3 Complex / Q000276:immunology; D066246:ErbB Receptors / Q000276:immunology; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007167:Immunotherapy; D000922:Immunotoxins / Q000276:immunology / Q000627:therapeutic use; D051379:Mice; D008819:Mice, Nude; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D015202:Protein Engineering; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis* / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use*; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014407:Tumor Cells, Cultured
D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D066246:ErbB Receptors; D000922:Immunotoxins; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins